C

Corline Biomedical AB
STO:CLBIO

Watchlist Manager
Corline Biomedical AB
STO:CLBIO
Watchlist
Price: 17 SEK -1.16% Market Closed
Market Cap: 416.3m SEK

Corline Biomedical AB
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Corline Biomedical AB
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
C
Corline Biomedical AB
STO:CLBIO
Revenue
kr7.6m
CAGR 3-Years
-26%
CAGR 5-Years
37%
CAGR 10-Years
24%
Calliditas Therapeutics AB
STO:CALTX
Revenue
kr1.6B
CAGR 3-Years
1 488%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Orexo AB
STO:ORX
Revenue
kr543.4m
CAGR 3-Years
-4%
CAGR 5-Years
-6%
CAGR 10-Years
-2%
Camurus AB
STO:CAMX
Revenue
kr2.4B
CAGR 3-Years
39%
CAGR 5-Years
55%
CAGR 10-Years
24%
S
Swedencare AB (publ)
STO:SECARE
Revenue
kr2.7B
CAGR 3-Years
19%
CAGR 5-Years
73%
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Revenue
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Corline Biomedical AB
Glance View

Market Cap
416.3m SEK
Industry
Pharmaceuticals

Corline Biomedical AB engages in the research, development, and commercialization of heparin based solutions. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-06-03. The company develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in regenerative medicine.

CLBIO Intrinsic Value
26.47 SEK
Undervaluation 36%
Intrinsic Value
Price
C

See Also

What is Corline Biomedical AB's Revenue?
Revenue
7.6m SEK

Based on the financial report for Sep 30, 2025, Corline Biomedical AB's Revenue amounts to 7.6m SEK.

What is Corline Biomedical AB's Revenue growth rate?
Revenue CAGR 10Y
24%

Over the last year, the Revenue growth was -46%. The average annual Revenue growth rates for Corline Biomedical AB have been -26% over the past three years , 37% over the past five years , and 24% over the past ten years .

Back to Top